⭐NAR Breakthrough! ⭐
Back-to-back NAR studies show #Palbociclib binds #HIV TAR RNA with low affinity & striking specificity. Induced-fit RNA refolding creates a #druggable pocket, blocking #SEC recruitment.📖 Read the articles here: doi.org/10.1093/nar/... doi.org/10.1093/nar/... #DrugDiscovery

ONCOLOGY NEWS: Updated PATINA Trial Results - catch-up with a quick Clinical Summary here: t.ly/uvjhe #PATINA #Palbociclib #HER2+MBC #metastaticbreastcancer

New @nejm.org | PATINA ph 3 trial | Adding #Palbociclib significantly improves progression-free survival in patients w/ HR+ HER2+ metastatic #BreastCancer | Prolonged disease control for an incurable condition | bit.ly/PATINAresults

Medical Product Alert N°7/2025: Falsified IBRANCE (palbociclib) Alert SummaryThis WHO Medical Product Alert refers to nine lots of falsified IBRANCE (palbociclib). These falsified products have been detected in Cote d’Ivoire, Egypt, Lebanon, Libya and Türkiye and ...

@who.int alerts about 9 lots of #falsified #IBRANCE ( #palbociclib) for breast #cancer, detected in #CotedIvoire, #Egypt, #Lebanon, #Libya, #Türkiye. Offered online & found at pharmacy level, they do NOT contain active ingredient, with high #risk of death.
www.who.int/news/item/15...

A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib’s Journey from Discovery to Approval and What’s Next in CDK Inhibition in Breast Cancer The approval of the first CDK4/6 inhibitor palbociclib in 2015 marked the beginning of a new era in breast cancer treatment. Follow its journey, from discovery to approval, and see what the future…

The approval of the first CDK4/6 inhibitor #palbociclib in 2015 marked the beginning of a new era in #BreastCancer treatment.

Follow its journey, from discovery to approval, and see what the future holds for CDK inhibition.

👉 buff.ly/kFWhGeF

#OncSky

#RecercaUB | Publicat a la revista #Oncogene, del grup @nature.com, el nou treball científic és de caràcter preclínic.

#fàrmac #palbociclib #càncercolorectal

Shifting First-Line Strategy: Inavolisib Shows OS, PFS Gains in INAVO120 Trial | Docwire News INAVO120 shows OS benefit with inavolisib in PIK3CA-mutated HR+/HER2– aBC, raising new considerations for first-line care.

#INAVO120: Neue Hoffnung für Patientinnen mit #PIK3CA-mutiertem HR+/HER2- Brustkrebs! Auf dem #ASCO2025 stellte Prof. Sibylle Loibl die finale OS-Analyse vor: +7 Monate medianes Überleben mit #Inavolisib + #Palbociclib + #Fulvestrant in der First-Line-Therapie
www.docwirenews.com/post/shiftin...

Sibylle Loibl: Final survival Results from the PENELOPE-B trial published in Annals of Oncology - OncoDaily Sibylle Loibl: Final survival Results from the PENELOPE-B trial published in Annals of Oncology / A. Antón Torres, A. Makris, Annals of Oncology, Breast

Final survival Results from the PENELOPE-B trial published in Annals of Oncology - Sibylle Loibl

oncodaily.com/insight/siby...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #PENELOPE-B #Palbociclib #BreastCancer

Primary results from a phase 2a study show #Zanidatamab + #Palbociclib + #Fulvestrant is a promising chemotherapy-free option for heavily pretreated HR+/HER2+ MBC patients.

@thelancetoncol.bsky.social

#Onco404 #Cancer #Kanser #BreastCancer #ClinicalTrials #HER2 #ADC #TDXd #Healthcare #Innovation

New—overall survival results from Young-PEARL:

#Palbociclib plus #endocrinetherapy versus capecitabine in #premenopausal women with hormone receptor-positive, HER2-negative metastatic #breastcancer

Elisa Agostinetto: Drug-drug interactions between palbociclib and PPI in breast cancer - OncoDaily Elisa Agostinetto: Drug-drug interactions between palbociclib and PPI in breast cancer / A DeMichele, Breast Cancer, C. Fesl, cancer, D. Hlauschek, D.R. Lu,

Drug-drug interactions between palbociclib and PPI in breast cancer - Elisa Agostinetto
@elisaagostinetto.bsky.social

oncodaily.com/insight/217982

#OncoDaily #Oncology #Palbociclib #PALLAStrial #Medicine #Health #Cancer

Palbonix 125mg (Palbociclib) | Order Now At IEB Pharma It is a which is useful to treat Palbonix 125mg (Palbociclib) HR-positive and HER2-negative breast cancer. This medicine falls in the class of inhibitors.

The recommended dose of Palbociclib is a 125 mg capsule taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days.
#Palbonix125mg #Palbociclib #IebPharma #AntiCancer #AntiViral #BreastCancer
iebpharma.com/product/palb...

Untitled link

🔴 Adding #palbociclib to treatment boosts progression-free survival by 15 months in metastatic RH+/HER2+ breast cancer.

🩺💊 Results shared at @sabcs.bsky.social, with Dr. Escriva recognized as the top recruiter for the trial.

➡️ linke.to/PATINASOLTIV...

#MamaVHIO

2. #PATINA: Ph 3, #palbociclib + Anti-HER2 + ET vs. anti-HER2 + ET after induction chemo for HR+ & HER2+ MBC:

- mPFS of 44.3mos w/ Palbo vs 29.1mos SoC (HR: 0.74)
- OS not mature yet
- New SoC for this subset